BTG BEGINS OSTEOARTHRITIS OF KNEE DRUG EFFICACY STUDY.
Injections of sodium hyaluronate into the knee have been shown to reduce pain associated with osteoarthritis of the knee by augmenting elastoviscosity within the joint. The current worldwide market for viscoelastic products for osteoarthritis of the knee is approximately $400 million, and is expected to grow as the aging population increases.
BTG's chairman and CEO, Sim Fass, stated: "The increasing elderly population is creating a greater need and larger market potential for viscoelastic products for osteoarthritis. We believe, therefore, that BioHy could have an important role to play in the market for such products."
Bio-Technology General Corp., a leading biopharmaceutical company, develops, manufactures and markets genetically engineered and other products for human health care. BTG's products are marketed in over thirty countries worldwide.
For more information, call 732-632-8800.
|Printer friendly Cite/link Email Feedback|
|Comment:||BTG BEGINS OSTEOARTHRITIS OF KNEE DRUG EFFICACY STUDY.|
|Date:||Oct 1, 1999|
|Previous Article:||FDA REQUESTS MODIFICATIONS TO BLA FOR BEXXAR.|
|Next Article:||ARGOMED GETS FDA APPROVAL FOR TREATMENT OF BPH.|
|Significant findings in recent glucosamine/chondroitin trials could boost sales growth.|